SCHEMBL2854619

SCHEMBL2854619

Cc1sc(-c2cc(CCc3ccccc3)cc(C(F)(F)F)c2)nc1Cn1cc(C(=O)O)cn1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTSS P25774 1/20 0.39
EGLN1 Q9GZT9 2/20 0.39
S1PR1 P21453 1/20 0.38
S1PR3 Q99500 1/20 0.38
RARA P10276 1/20 0.38
RARB P10826 1/20 0.38
RARG P13631 1/20 0.38
KLKB1 P03952 2/20 0.38
NR1H4 Q96RI1 1/20 0.37
ALDH1A1 P00352 2/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
PPARG P37231 2/20 0.36
PPARA Q07869 2/20 0.36
DHODH Q02127 1/20 0.36
PTPN1 P18031 1/20 0.36
ADORA2A P29274 1/20 0.36
ADORA2B P29275 1/20 0.36
ADORA1 P30542 1/20 0.36
KDM4E B2RXH2 1/20 0.36
MEN1 O00255 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2857069 0.89 PPARG (0.43) CTSSPPARGPPARAPTPN1PPARD
SCHEMBL12876052 0.88 DHODH (0.42) EGLN1RARARARBRARGKLKB1
SCHEMBL2859204 0.87 ALKBH1 (0.41) CTSSEGLN1KLKB1PPARGPPARA
SCHEMBL1198840 0.86 ALDH1A1 (0.53) EGLN1RARARARBRARGNR1H4
SCHEMBL1198548 0.86 EGLN1 (0.39) CTSSEGLN1S1PR1S1PR3KLKB1
SCHEMBL1198731 0.86 RXRA (0.37) CTSSEGLN1KLKB1NR1H4ALDH1A1
SCHEMBL1198313 0.85 ALDH1A1 (0.37) CTSSEGLN1S1PR1S1PR3RARA
SCHEMBL1198312 0.85 ALDH1A1 (0.37) CTSSEGLN1S1PR1S1PR3RARA
SCHEMBL1199073 0.85 EGLN1 (0.38) CTSSEGLN1RARARARBRARG
SCHEMBL1197847 0.84 MMP13 (0.41) KLKB1PPARGDGAT2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8461348-B2 Heterocyclic derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-06-11 US disclosed
US-8461348-B2 Heterocyclic derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-06-11 US disclosed
US-20110028493-A1 HETEROCYCLIC DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-02-03 US disclosed
EP-2264017-A1 HETEROCYCLIC DERIVATIVE AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2010-12-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110028493-A1 HETEROCYCLIC DERIVATIVE AND USE THEREOF PDE3B, PDE5A, PDE2A CTSS 4641/4885EGLN1 829/4885S1PR1 2579/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.